Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer

Abstract

PurposeThere are significant differences in the biological behavior between triple-negative breast cancer (TNBC) and non-triple-negative breast cancer (non-TNBC). In the present study, we identify key differential genes and clinical outcomes between TNBC and non-TNBC.Materials and methodsTranscriptomic analyses used GEO datasets (GSE76275), gene ontology, KEGG pathway analysis and cBioPortal. Quantitative RT-PCR analysis (qRT-PCR) was used to validate the differentially expressed genes. We used the KM Plotter Online Tool and 240 patients with TNBC tissue microarray to assay the prognostic value of HORMAD1.ResultsThe upregulated differentially expressed genes were enriched in transcription factor activity, sequence-specific DNA binding and nucleic acid binding transcription factor activity. Only 16 genes were upregulated when further screened for fold change >4-fold change. HORMAD1 and SOX8 exhibited high frequencies of change of greater than 10% (HORMAD1 was close to 20%). qRT-PCR results indicated that HORMAD1 and SOX8 mRNA levels were significantly upregulated in TNBC samples. In KM Plotter Online Tool, high HORMAD1 was associated with worse outcome. In our tissue microarray (including 240 TNBC tissues), IHC analysis revealed that 29.7% (55/240) of the tumor samples exhibited high HORMAD1 expression and 70.3% (185/240) of the tumor samples exhibited low HORMAD1 expression levels. Meanwhile, high HORMAD1 group has a bad prognosis.ConclusionThe status of transcriptional activation is an important difference between TNBC and non-TNBC. HORMAD1 is a key differential gene associated with poor outcome in TNBC. Epigenetic therapy and agents targeting cancer/testis antigens might potentially help to customize therapies of TNBC.

Adverse effects of being underweight on young female breast cancer patients with lymph node metastases

“…In 2014, the prevalence of underweight in women in South Asian countries was still 24.0% [8]. Breast cancer is the highest incidence of malignant tumors all over the world amongst women [9,10]. It is meaningful to explore the relation of low body mass index to the prognosis of breast cancer.…”

Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers

“…Therefore, it is necessary to clarify the role of S1PR1 in tumor development and progression. Transcriptome analysis can be used to predict important issues, such as the intrinsic subtype of the primary tumor, tumor grade, drug reactivity, and recurrence risk [18][19][20].…”

<p>MicroRNA-139 Suppresses the Tumorigenicity of Triple Negative Breast Cancer Cells by Targeting SOX8</p>

“…[16][17][18] SOX8 as a functional oncogene that is involved in the maintenance of stem-like capacities in TNBC cells, and its high expression has been significantly associated with poor prognosis in TNBC patients. 19,20 However, whether miR-139 modulates TNBC cells and the underlying molecular mechanisms remain unclear. In this study, the dual-luciferase reporter assay was performed to confirm that miR-139 targets SOX8 in HCC1806 and BT549 cells.…”